Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3251
Embecta
EMBC
$290M
| $1.25M | ﹤0.01% |
105,156
+8,487
| +9% | +$112K |
|
|
ZBIO
3252
Zenas BioPharma
ZBIO
$1.84B
| $1.25M | ﹤0.01% |
34,377
+11,501
| +50% | +$378K |
|
3253
Transcat
TRNS
$888M
| $1.24M | ﹤0.01% |
21,924
+2,091
| +11% | +$130K |
|
3254
Vanguard Total World Stock ETF
VT
$81.9B
| $1.24M | ﹤0.01% |
8,808
-6,242
| -41% | -$873K |
|
3255
PUT
Dyne Therapeutics
DYN
$4.85B
| $1.24M | ﹤0.01% |
63,300
| – | – |
|
3256
Veritone
VERI
$139M
| $1.24M | ﹤0.01% |
266,042
+206,025
| +343% | +$1.11M |
|
3257
Bank of Marin Bancorp
BMRC
$462M
| $1.24M | ﹤0.01% |
47,488
+2,232
| +5% | +$57.4K |
|
3258
Smith & Nephew
SNN
$12.6B
| $1.23M | ﹤0.01% |
+37,619
| New | +$1.29M |
|
3259
Compass Minerals
CMP
$1.1B
| $1.23M | ﹤0.01% |
62,817
+6,239
| +11% | +$115K |
|
3260
First Bancorp
FNLC
$401M
| $1.23M | ﹤0.01% |
46,655
-1,389
| -3% | -$35.8K |
|
|
UHT
3261
Universal Health Realty Income Trust
UHT
$573M
| $1.23M | ﹤0.01% |
31,314
+1,774
| +6% | +$69.2K |
|
3262
Edgewell Personal Care
EPC
$1.31B
| $1.23M | ﹤0.01% |
71,986
+3,112
| +5% | +$57.6K |
|
3263
Liberty Live Group Series C
LLYVK
$9.92B
| $1.22M | ﹤0.01% |
14,709
+8,933
| +155% | +$767K |
|
3264
Matthews International
MATW
$722M
| $1.22M | ﹤0.01% |
46,813
+4,563
| +11% | +$112K |
|
3265
Movado Group
MOV
$796M
| $1.22M | ﹤0.01% |
59,057
-499
| -0.8% | -$9.73K |
|
3266
Red Violet
RDVT
$1.18B
| $1.22M | ﹤0.01% |
21,364
+2,132
| +11% | +$116K |
|
3267
PRA Group
PRAA
$762M
| $1.22M | ﹤0.01% |
68,733
+646
| +0.9% | +$10.1K |
|
3268
Ramaco Resources Class A
METC
$667M
| $1.21M | ﹤0.01% |
67,269
-72,172
| -52% | -$1.9M |
|
3269
Business First Bancshares
BFST
$1.05B
| $1.21M | ﹤0.01% |
46,210
+6,091
| +15% | +$154K |
|
3270
Blend Labs
BLND
$367M
| $1.21M | ﹤0.01% |
397,203
+6,001
| +2% | +$19.1K |
|
3271
Hovnanian Enterprises
HOV
$799M
| $1.21M | ﹤0.01% |
12,369
+2,656
| +27% | +$313K |
|
|
CMBT
3272
CMB.TECH NV
CMBT
$4.92B
| $1.21M | ﹤0.01% |
124,917
+91,622
| +275% | +$891K |
|
3273
CNB Financial Corp
CCNE
$1.04B
| $1.19M | ﹤0.01% |
45,599
+6,167
| +16% | +$156K |
|
|
ALMS
3274
Alumis Inc
ALMS
$3.11B
| $1.19M | ﹤0.01% |
122,210
+38,842
| +47% | +$271K |
|
|
GOLD
3275
Gold.com Inc
GOLD
$1.27B
| $1.19M | ﹤0.01% |
35,027
+8,083
| +30% | +$231K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.